A global boutique that became part of Ashfield Advisory—itself owned by UDH Healthcare—in 2019, Putnam Associates has maintained the brand and culture that made it a success, while gaining the ability to scale more rapidly across the healthcare and biopharmaceutical industries. Beyond the firm’s commitment and expertise to revolutionizing life sciences consulting is a determination to “bring out the best in each other.” Putnam’s commitment to development makes it a great choice for anybody looking to acquire practical knowledge of the ...
Major Departments/Practice Areas
Major Office Locations
A firm that has always had a strong reputation for being a people-first, culture-centric employer, we were understandably interested to hear what Putnam Group’s consultants had to say on life at the firm 18 month after being acquired. The good news is that it’s good news: that culture and focus have remained largely intact, with the acquisition simply adding scale, reach, and the ability to tap additional resources through its parent company.
With that in mind, it’s no surprise that Putnamites feel bullish about the future, or that they continue to love life at an outfit that still looks, feels and acts very much like an independent boutique. Work hours and travel—two of the banes of the industry—continue to be well-managed and kept to a minimum at the firm, whil...
For more than 30 years Putnam Associates operated independently, growing into a premier strategy consulting firm serving biopharmaceutical, biotechnology (cell, gene and tissue therapies), diagnostics, medical device, and related clients in the healthcare space. Today, following an acquisition in 2019, the firm continues to operate under the Putnam name, but as a unit of Ashfield Advisory, a firm that is itself owned by UDH Healthcare.
Putnam provides objective, high impact strategic advice and analytical services, helping to support clients in crucial business decisions at all stages of the product and franchise lifecycle. The firm's clients range from venture-backed biotechs to Fortune 500 companies, including the majority of the world's major biopharmaceutical companies–indeed, despite being based in the US, more than ha...